Cleveland-Cliffs Stock Climbs As Wall Street Turns Bullish

Cleveland-Cliffs Inc. jumps as bullish steel demand outlook boosts investor confidence, and stocks have been trading up by 6.49 percent

Live Update At 16:47:07 EDT: On Friday, October 09, 2026 Cleveland-Cliffs Inc. stock [NYSE: CLF] is trending up by 6.49%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Cleveland-Cliffs (CLF) has quietly turned its chart around. Over the past few weeks, the stock has pushed from the $11 area to close near $12.98, with multiple strong green days and higher lows along the way. For short-term traders, that’s a clear sign of renewed momentum. The intraday tape on the latest session shows CLF grinding higher most of the day, topping out above $13 before settling just under that level, with tight 5‑minute candles and controlled dips. That’s the kind of orderly strength momentum traders like to stalk.

Under the hood, the Cleveland-Cliffs fundamentals still show a cyclical, leveraged steel name. Revenue over the last year sits around $18.61B, but margins are thin to negative, with recent profit margins below zero. The latest quarterly income statement shows a net loss of about $145M on $5.226B in revenue, while adjusted EBITDA was a positive $266M, highlighting how depreciation and interest weigh on reported earnings.

CLF carries meaningful debt, with total liabilities near $14.3B and long-term debt around $7.7B. But liquidity is decent, with a current ratio near 1.9. For traders, that mix says: earnings are volatile, but cash generation and leverage are manageable if the steel cycle stays firm.

Why Traders Are Watching CLF’s Momentum

Right now CLF is a pure sentiment and cycle story, and that’s why traders are crowding in. Cleveland-Cliffs has told the Street to expect Q3 2026 adjusted EBITDA of about $575M, up sharply from $286M in the prior quarter, and management is already signaling further improvement into the next quarter. For a cyclical steel producer, nearly doubling EBITDA in one quarter is a big deal. It tells traders the pricing and volume backdrop has turned in CLF’s favor.

Wall Street is reacting. GLJ Research lifted its CLF target from $15.60 to $17.48 after management suggested Q4 EBITDA could reach roughly $700M. That’s not a small tweak. GLJ is now modeling Q3 and Q4 EBITDA about 15% and 25% above consensus, respectively, which implies the Street may still be underestimating Cleveland-Cliffs’ earnings power.

Wells Fargo followed with an upgrade to Overweight and a target hike to $14, leaning on expected steel pricing power and the potential for 2H26–2027 EBITDA to “materially exceed” consensus. At the same time, other firms like JPMorgan remain more cautious, only bumping their CLF target to $13 and sticking with a Neutral stance. The average target for Cleveland-Cliffs still sits near $13.04 and the consensus rating is effectively Hold.

For active traders, that split view is opportunity. If CLF delivers numbers near GLJ’s and Wells Fargo’s bullish scenarios on 2026/10/19, reluctant analysts may have to play catch‑up, which often fuels fast re‑rating moves.

Conclusion

Cleveland-Cliffs is also working the long game. The company is showcasing a $200M Grain Oriented Electrical Steel expansion at its Butler Works facility, supported by a $75M U.S. Department of Energy award. That project could lift GOES output by up to 25% and cements CLF as the only U.S. producer of this specialty steel for electrical transformers. With the U.S. President touting a planned $15B Mesabi Metallics steel facility in Iowa and broader grid investment themes in play, CLF sits in the sweet spot of domestic steel and infrastructure demand.

At the same time, Cleveland-Cliffs is still not a low‑risk balance sheet story. Margins are thin, leverage is real, and recent GAAP results show a net loss despite positive EBITDA. Form 4 filings also show insider activity in CLF, though details are too sparse to lean on as a clear signal. That’s exactly why traders must stay tactical — watch price action, watch guidance, and be ready to cut losses quickly if the story shifts. As millionaire penny stock trader and teacher Tim Sykes, says, “Cut losses quickly, let profits ride, and don’t overtrade.” — a trading mantra that applies directly to navigating a volatile cyclical name like CLF.

The key near‑term catalyst is clear: Q3 2026 earnings and the 2026/10/19 call. If CLF prints EBITDA near $575M and points confidently toward that roughly $700M Q4 number, the bullish case from GLJ and Wells Fargo gains serious weight. As Tim Sykes likes to say, “The market rewards preparation, not predictions.” For CLF, that means coming into earnings with a plan, clear levels, and the discipline to react, not hope.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks